Fig 1.
Literature search and study selection.
Fig 2.
Bubble chart displaying studies included in review by study year, geographic region, and type of economic evaluation.
Balloon size depicts the number of citations through Google Scholar.
Fig 3.
Data sources used by LD cost-effectiveness analyses and cost analyses.
* New Jersey Blue Cross—Blue Shield; Diversified Pharmaceutical Services; Delmarva Health Plan; Swedish Social Insurance; German DAK; IMS Health LifeLink Health Plan Claims; ** CDC LD Incidence Reports, Epidemiologic Reports, Lyme Disease Vaccine Study Group; *** Scottish Health Service, Departments of Economy and Information Technology.
Table 1.
Economic evaluation study characteristics.
Table 2.
Primary study characteristics and conclusions of cost-effectiveness analyses.
Table 3.
Summary of standardized ICER for vaccination programs in the United States.
Table 4.
Primary study characteristics and conclusions of cost analyses.